Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Narayanan to lead SeQuent through next phase of consolidation and growth
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
The study will be published on the pre-print server, medRXiv, shortly
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Subscribe To Our Newsletter & Stay Updated